Navigation Links
ThromboGenics NV - Q3 2009 Business Update
Date:11/4/2009

LEUVEN, Belgium, November 4 /PRNewswire-FirstCall/ -- ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on innovative medicines for eye disease, vascular disease and cancer, is today issuing a business update for the period ending 30 September, 2009.

Patrik De Haes, CEO of ThromboGenics, said:

"ThromboGenics' clinical development programs have continued to make significant progress. We are very happy to have completed patient enrolment for the US Phase III study with microplasmin and recruitment in our second Phase III trial is continuing to make excellent progress. Microplasmin is central to our aim of building a successful integrated company focused on cutting edge ophthalmic medicines, that is positioned to deliver significant shareholder value.

We have also recently completed patient recruitment of a Phase II study with TB-402, assessing it as a DVT prophylactic in patients undergoing knee replacement, ahead of schedule. Our experience with TB-402 suggests that this long acting product has the potential to be an important new entrant into the anticoagulant market making it an attractive out-licensing opportunity. Our partnership with Roche for the novel anti-cancer antibody TB-403 continues to make good progress, with results from the Phase Ib trial to be presented later this month at the American Association for Cancer Research conference."

    Financial Update

    - ThromboGenics achieved revenues of EUR3.7 million in the
      third quarter of 2009, the majority of which came from out-licensing.
      R&D expenses were EUR12.6 million during this nine month period. In
      Addition EUR10.4 million of expenses related to the microplasmin Phase
      III clinical program have been capitalized over the first nine months
      of this year.
    - As of September 30, 2009, ThromboGenics had EUR43.1 million
      in cash and cash equivalents. This compares to 
'/>"/>
SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
2. ThromboGenics is Shortlisted for "Biotech Company of the Year" and "Licensing Deal of the Year" at Scrip Awards 2009
3. ThromboGenics NV Announces Business Update and Half Year Results 2009
4. ThromboGenics NV: Business Update
5. ThromboGenics Announces Business Update and 2008 Full Year Results
6. ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis
7. ThromboGenics N.V.: Business Update
8. ThromboGenics Announces Half Year Results 2008
9. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
10. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
11. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2015)... 2015 This year has been one ... US Patented Pearl’s Premium Ultra Low Maintenance Lawn ... country that are coming out of record bad weather. ... of major global concerns related to water, health, and ... the alternative to the standard, water-wasting, chemical-treated standard lawn. ...
(Date:5/20/2015)... The global genotyping market is expected to grow ... of 2015 to 2020 to reach $17.0billion in 2020. ... and development process and to provide personalized therapy, factors ... investments by key manufacturers to offer advanced and innovative ... Browse 113 market data tables & 37 figures spread ...
(Date:5/20/2015)...  Marc Tessier-Lavigne, president of The Rockefeller University, ... from The Marie-Josée and Henry R. Kravis Foundation ... will be the centerpiece of the University,s major ... Kravis Research Building, two stories high, will be ... city blocks following the shoreline of the East ...
(Date:5/20/2015)... , May 20, 2015  Resolution Bioscience announced today ... ctDx ALK TM , a blood-based liquid biopsy for ... lung carcinoma (NSCLC), the most common form of this ... to guide patients to personalized therapies and direct them ... The Department of Health, the CLIA authority in ...
Breaking Biology Technology:Breakthrough 4th Generation Low Maintenance Lawn Seed Offers Solution to California Drought 2Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 2Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 3Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 4Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 5The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 2The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 3The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 4Resolution Bioscience Receives CLIA Certification for its Diagnostic Laboratory and Launches CLIA-Certified Liquid Biopsy for Lung Cancer 2
... Batey, Ph.D.2 , and Brendan Bohannan, Ph.D.1 , ... , , ... , Abstract , ... to measure the ammonia-oxidizing bacteria (AOB) population in soils maintained under 16 environmental regimes.,DNA was ...
... , AquaPure Genomic DNA Isolation ... range: 100300 g DNA, , Method ... 1. Use fresh blood within 10 sec of venipuncture to avoid clotting. Alternatively, , ... reduce , DNA degradation. Blood may be either fresh or frozen. ...
... , , , ... gel support frame, used with the Trans-Blot , ... from agarose gels to nylon membrane in minutes, without any gel pretreatments. , ... generates a , high field strength (V/cm 2 ...
Cached Biology Technology:Monitoring Microbial Populations Using Real-Time qPCR on the MJ Research Opticon 2 System 2Monitoring Microbial Populations Using Real-Time qPCR on the MJ Research Opticon 2 System 3Monitoring Microbial Populations Using Real-Time qPCR on the MJ Research Opticon 2 System 4Monitoring Microbial Populations Using Real-Time qPCR on the MJ Research Opticon 2 System 5Monitoring Microbial Populations Using Real-Time qPCR on the MJ Research Opticon 2 System 6Monitoring Microbial Populations Using Real-Time qPCR on the MJ Research Opticon 2 System 7Genomic DNA Isolation Protocol for 40 l Avian Whole Blood 2DNA/RNA Blotting With the Trans-Blot SD Semi-Dry Electrophoretic Transfer Cell 2
(Date:5/21/2015)... May 21, 2015 According ... Market by Solutions (Hardware, Software, Services), by Applications (Surveillance ... others), by End-Users (Military & Defense & Commercial) ... Thermal Imaging Market is expected to grow from ... 2020, at a Compound Annual Growth Rate (CAGR) ...
(Date:5/19/2015)... -- Technology is rapidly advancing, outpacing enterprises, ability to secure ... and their management are soon to be rendered obsolete ... as those developed by the FIDO Alliance™. With the ... BYOD, COPE, IoT, and mobile payments, the interconnected online ... In response to the call for seamless, secure, ...
(Date:5/11/2015)... 11, 2015  Synaptics Incorporated (NASDAQ: SYNA ... today announced the appointment of Wajid Ali ... Officer, reporting to Rick Bergman , President ... Financial Officer, Kathleen Bayless , who announced ... Mr. Ali brings extensive financial management expertise to ...
Breaking Biology News(10 mins):Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 2HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 3Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2
... 90 with preserved cognition, according to a study published ... Geriatric Psychiatry. The study, which was conducted at the ... genetic links to cognitive longevity. , "Successful aging has ... individuals who had reached at least 90 without significant ...
... of pharmaceuticals are studying cellular proteins called transcription factors, ... the expression of those genes on or off. Some ... selectively block the binding of transcription factors as a ... researchers at the University of California, San Diego on ...
... it's a daunting task to find a smoking gun ... to say not just when and how a specific ... translated into real-world dominance of one population over another. ... forced bacteria to compete in a head-to-head contest for ...
Cached Biology News:New research examines genetics of successful aging 2Cells use mix-and-match approach to tailor regulation of genes 2Ready, set, mutate?and may the best microbe win 2Ready, set, mutate?and may the best microbe win 3
SHEEP ANTI HUMAN ESTRONE...
Request Info...
... The CultureWell cell culture ... for preparing cultured cells for ... uses medical-grade silicone gaskets preassembled ... cell culture plates. The entire ...
... The Captivate magnetic separator ... be used in conjunction with ... C-21474, C-21476) or other magnetic ... most 96-well microplates. Cell Biology ...
Biology Products: